A former federal judge and director at a pharmaceutical company has dropped his lawsuit accusing national plaintiffs' law ...

Viatris said on Monday the U.S. Food and Drug Administration has restricted imports of 11 products made at the drugmaker's ...

Promising early results from an ongoing randomized, open-label, single-arm, Phase 3 study could pave the way for a Pfizer ...

The accelerated approval is part of the FDA’s Project FrontRunner, aimed at advancing cancer drug development.

Pfizer's efficiency at spending on R&D and Capex is set to look much better. Click here to see why PFE stock is a Buy.

It’s been a year of big stories about Big Pharmas in the healthcare marketing world. | It’s been a year of big stories about ...

Pfizer's dividend isn't the only thing going for it. UPS is poised to turn the corner after a few bad years for its stock. If ...

On Friday, Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $26.36 which represents a slight increase of $0.59 or 2.29% from the prior close of $25.77. The stock opened at $ and touched a ...

Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...